Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologic or cytologic diagnosis of pancreatic adenocarcinoma, or adenosquamous cancer, or any non-neuroendocrine primary pancreas variant, including acinar cancer.
De novo or recurrent diagnosis of previously untreated stage IV PDAC with intent to receive FOLFIRINOX/mFOLFIRINOX.
ECOG 0-2.
No use of pancreatic enzyme replacement therapy within prior 2 weeks.
Patients with biliary obstruction are eligible provided biliary stenting has or will occur before treatment with FOLFIRINOX.
Ability to understand and the willingness to sign an informed consent document.
